{"id":4650,"date":"2018-10-18T11:28:00","date_gmt":"2018-10-18T09:28:00","guid":{"rendered":"https:\/\/patientenstimme-sma.de\/?page_id=4650"},"modified":"2026-03-16T21:04:51","modified_gmt":"2026-03-16T20:04:51","slug":"neues-zur-zulassung-avxs-101","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/neues-zur-zulassung-avxs-101\/","title":{"rendered":"Neues zur Zulassung AVXS-101"},"content":{"rendered":"\n<p class=\"tw-text-wide\">Novartis gibt in einem Quartalsbericht an, f\u00fcr AVXS-101 gleichzeitig in den USA, Japan und auch der EU die Zulassung zu beantragen.<\/p>\n\n\n\n<p class=\"tw-text-wide\">Quelle:&nbsp;<a href=\"https:\/\/www.novartis.com\/news\/novartis-financial-results-q3-2018\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.novartis.com\/news\/novartis-financial-results-q3-2018<\/a><\/p>\n\n\n\n<p class=\"tw-text-wide\">Dort gibt es auch ein Video wo ca. ab Minute&nbsp; 1:38 eingeleitet und dann ca. ab 1:46 von Paul Hudson dar\u00fcber gesprochen wird.<\/p>\n\n\n\n<p class=\"tw-text-wide\"><a href=\"http:\/\/www.curesma.org\/news\/avexis-statement-fda-filing.html\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"color: #008000\"><strong>UPDATE:<\/strong><\/span><\/a> Und da ist es auch dann schon passiert. AveXis\/Novartis haben die Zulassung eingereicht.<\/p>\n\n\n\n<p class=\"tw-text-wide\"><a href=\"https:\/\/translate.google.com\/translate?sl=en&amp;tl=de&amp;js=y&amp;prev=_t&amp;hl=de&amp;ie=UTF-8&amp;u=http%3A%2F%2Fwww.curesma.org%2Fnews%2Favexis-statement-fda-filing.html&amp;edit-text=&amp;act=url\" target=\"_blank\" rel=\"noopener noreferrer\">Link \u00fcber Google-Translate zur direkten \u00dcbersetzung<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis gibt in einem Quartalsbericht an, f\u00fcr AVXS-101 gleichzeitig in den USA, Japan und auch der EU die Zulassung zu beantragen. Quelle:&nbsp;https:\/\/www.novartis.com\/news\/novartis-financial-results-q3-2018 Dort gibt es auch ein Video wo ca. ab Minute&nbsp; 1:38 eingeleitet und dann ca. ab 1:46 von Paul Hudson dar\u00fcber gesprochen wird. UPDATE: Und da ist es auch dann schon passiert. AveXis\/Novartis [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-4650","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=4650"}],"version-history":[{"count":1,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4650\/revisions"}],"predecessor-version":[{"id":39893,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4650\/revisions\/39893"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=4650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=4650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=4650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}